PDF(Pubmed)
Abstract：
High-grade neuroendocrine neoplasms are a rare disease entity and account for approximately 10% of all neuroendocrine neoplasms. Because of their rarity, there is an overall lack of prospectively collected data available to advise practitioners as to how best to manage these patients. As a result, best practices are largely based on expert opinion. Recently, a distinction was made between well-differentiated high-grade (G3) neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas, and with this, pathologic details, appropriate imaging practices and treatment have become more complex. In an effort to provide practitioners with the best guidance for the management of patients with high-grade neuroendocrine neoplasms of the gastrointestinal tract, pancreas, and gynecologic system, the North American Neuroendocrine Tumor Society convened a panel of experts to develop a set of recommendations and a treatment algorithm that may be used by practitioners for the care of these patients. Here, we provide consensus recommendations from the panel on pathology, imaging practices, management of localized disease, management of metastatic disease and surveillance and draw key distinctions as to the approach that should be utilized in patients with well-differentiated G3 neuroendocrine tumors vs poorly differentiated neuroendocrine carcinomas.
摘要：
高级别神经内分泌肿瘤（G3NET）和神经内分泌癌（NEC）是一种罕见的疾病实体，可获得的前瞻性数据有限。G3NET和NEC之间的区别也相对较新，进一步复杂化的管理方法。由于这个空间的数据总体上缺乏，许多治疗这些肿瘤的实践是基于预期的意见。北美神经内分泌肿瘤协会（NANETS）是由专门管理这些肿瘤的专家组成的组织。为了向肿瘤学界提供有关这些罕见肿瘤的管理的进一步指导，NANETS召集了一个来自肿瘤学的专家小组，手术,介入放射学,核医学,放射学,病理学和放射肿瘤学，以解决围绕G3NET和NEC管理的关键问题，这些问题将受益于专家共识意见。在这里，我们提出了这个神经内分泌专家小组关于高等级管理的建议，肺外神经内分泌肿瘤（G3NET）和神经内分泌癌（NEC）。
